Recurrence of upper aerodigestive tract tumors;Les récidives des tumeurs des voies aérodigestives supérieures

Bulletin du Cancer

Volumn 101, Issue 5, 2014, Pages 511-520

  Martin, Laurent ^a   Zoubir, Mustapha ^b   Le Tourneau, Christophe ^b  

^a Guillaume le Conquérant Center   (France)

^b INSTITUT CURIE   (France)

Author keywords

Cancer; Chemotherapy; Head and neck; Radiotherapy; Recurrence; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; NANOPARTICLE;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DIGESTIVE SYSTEM TUMOR; DRUG DELIVERY SYSTEM; HUMAN; MULTIMODALITY CANCER THERAPY; REVIEW; TUMOR RECURRENCE; UPPER AERODIGESTIVE TRACT TUMOR; UPPER GASTROINTESTINAL TRACT;

CANCER; CHEMOTHERAPY; HEAD AND NECK; RADIOTHERAPY; RECURRENCE; SURGERY;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; LYMPH NODES; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; RADIOTHERAPY;

EID: 84903215090     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2014.1970     Document Type: Article

References (41)

1. Cooper JS, Pajak TF, Forastiere AA. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350 : 1937-44.
2. Kim AJ, Suh JD, Sercarz JA. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. Laryngoscope 2007; 117 : 1019-23. (Pubitemid 46869838)
3. Ho AS, Kraus DH, Ganly I. Decision making in the management of recurrent head and neck cancer, 2012. doi: 10.1002/hed.23227, Published online in Wiley Online Library (wileyonlinelibrary.com).
4. Janot F, de Raucourt D, Benhamou E. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26 : 5518-23.
5. Agra IM, Carvalho AL, Ulbrich FS. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck 2006; 28 : 107-13. (Pubitemid 43152704)
6. Stell PM. Time to recurrence of squamous cell carcinoma of the head and neck. Head Neck 1991; 13 : 277-81.
7. Lim JY, Lim YC, Kim SH, Byeon HK, Choi EC. Factors predictive of successful outcome following salvage treatment of isolated neck recurrences. Otolaryngol Head Neck Surg 2010; 142 : 832-7.
8. Thariat J, Jegoux F, Pointreau Y, et al. Évolution des concepts dans les cancers des voies aérodigestives supérieures, sous l'égide de l'Intergroupe ORL (GORTEC, GETTEC, GERCOR). Bull Cancer 2013; 100 : 983-97.
9. Deschamps DR, Spencer HJ, Kokoska MS, Spring PM, Vural EA, Stack Jr. BC. Implications of head and neck cancer treatment failure in the neck. Otolaryngol Head Neck Surg 2010; 142 : 722-7.
10. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ. Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Semin Radiat Oncol 2004; 14 : 190-5. (Pubitemid 38586112)
11. Goodwin Jr. WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000; 110(3 Pt 2 Suppl 93) : 1-18. (Pubitemid 30141742)
12. Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA. Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011; 80 : 669-76.
13. De Crevoisier R, Bourhis J, Domenge C. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998; 16 : 3556-62. (Pubitemid 28506768)
14. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008; 30 : 281-8. (Pubitemid 351480742)
15. Wong CJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol 2006; 24 : 2653-8. (Pubitemid 46622086)
16. Bonner A, Harari PM, Giralt J. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11 : 21-8.
17. Comet B, Kramar A, Faivre-Pierret M, et al. Salvage stereotactic reirradiation with or without cetixumab for locally recurrent head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2012; 84 : 203-9.
18. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 : 1116-27. doi: 10.1056/NEJMoa0802656.
19. Guigay J, Fayette J, Dillies A, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): first results of phase II trial GORTEC 2008-03. J Clin Oncol 2011 ; 29 (suppl ; abstr 5567).
20. Posner MR, Haddad RI, Wirth L, et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004; 31 : 778-85. (Pubitemid 39602683)
21. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53 : 3579-84. (Pubitemid 23229640)
22. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11 : 1873-8. (Pubitemid 23304610)
23. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24 : 2666-72. (Pubitemid 46622088)
24. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007 ; 1773 : 1263-84 [Epub 2006 Oct 7. Review].
25. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7 : 301-11. (Pubitemid 40544648)
26. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6 : 714-27. (Pubitemid 44286003)
27. Prakash P, Runhua S, Lori P, et al. Cisplatin (CDDP) and radiation versus cetuximab (Cx) and radiation in locally advanced head and neck squamous cell cancer (SCHNC): A retrospective review. 2012 ASCO Annual Meeting. J Clin Oncol 2012; 30 (suppl; abstr e16009).
28. Vermorken JB, Mesia R, Rivera F. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. JCO 2007; 25 : 2171-7. (Pubitemid 46954639)
29. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10 : 558-65.
30. Rebucci M, Peixoto P, Dewitte A, et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol 2011; 38 : 189-200.
31. Günthert U, Hofmann M, Rudy S, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65 : 13-24. (Pubitemid 121001209)
32. Naor D, Sionov RV, Ish-Shalom D. CD44: Structure, function and association with the malignant process. In : Vande Woude GF, Klein G, eds. Advances in cancer research. San Diego : Academic Press, 1997, p. 243-318.
33. Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004; 20 : 529-38. (Pubitemid 38638123)
34. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27 : 195-201.
35. Riley JL. PD-1 signaling in primary T cells. Immunological Reviews 2009; 229 : 114-25.
36. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63 : 6501-5. (Pubitemid 37255203)
37. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 2011; 47 : 1148-53.
38. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73 : 1733-41.
39. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7- H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8 : 793-800.
40. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101 : 17174-9. (Pubitemid 39627793)
41. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28 : 3167-75.